M

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. PC10807ACJG First Named Inventor or Application Identifier Evgenyi Y. Shalaev, et al Use of o-vanillin and o-vanillin/Trolox® Combinations

EL709320584US Express Mail Label No. Only for new nonprovisional applications under 37C.F.R. §1.53(b)) **Assistant Commissioner for Patents** APPLICATION ELEMENTS ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 6. Microfiche Computer Program (Appendix) *Fee Transmittal Form (e.g., PTO/SB/17) Submit an original, and a duplicate for fee processing) 7. Nucleotide and/or Amino Acid Sequence Submission 2 Total Pages Specification (if applicable, all necessary) (preferred arrangement set forth below) - Descriptive title of the Invention Computer Readable Copy Cross References to Related Applications b. Paper Copy (identical to computer copy) Statement Regarding Fed sponsored R&D Reference in Microfiche Appendix Statement verifying identity of above copies C. ACCOMPANYING APPLICATION PARTS - Background of the Invention Brief Summary of the Invention Assignment Papers (cover sheet & document(s)) 8. Brief Description of the Drawings (if filed) **Detailed Description** 9. 37 C.F.R. §3.73(b) Statement Power of Attorney Claim(s) (when there is an assignee) Abstract of the Disclosure English Translation Document (if applicable) 10. Copies of IDS Information Disclosure Drawing(s) (35 U.S.C. 11.3)[Total sheets Statement (IDS)/PTO-1449 Citations Oath or Declaration [Total pages 12. Preliminary Amendment Return Receipt Postcard (MPEP 503) Newly executed (original or copy) 13. (Should be specifically itemized) Copy from a prior application (37 CFR *Small Entity Statement filed in prior application, §1.63(d)) (for continuation/divisional with Box 17 completed) Statement(s) Status still proper and desired [Note Box 5 below] (PTO/SB/09-12) DELETION OF INVENTOR(S) Certified Copy of Priority Document(s) 15. Signed statement attached deleting (if foreign priority is claimed) inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b). Priority Claim of U.S. Provisional Application Incorporation By Reference (useable if Box 4b is checked) Other: No. 60/189,101, filed March 14, 2000. The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein. *NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28). If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment: Continuation Divisional Continuation-in-part (CIP) of prior application No: Prior application information: Examiner Group/Art Unit: 18. CORRESPONDENCE ADDRESS (Insert Customer No. or Attach bar code label here) Customer Number or Bar Code Label Correspondence address below Gregg C. Benson Name Address Pfizer Inc. Address Patent Department, MS 4159, Eastern Point Road State Zip Code 06340 City CT Groton United States Of America 1-(860)-441-4901 1-(860)-441-5221 Country Telephone NAME (Print/type) 39.203 Registration No. (Attorney/Agent) Carl J. Goddard Date 3/12/01 Signature

OMB 0651-00	032 Pat

			OMB 065	1-0032 Pat	redemark Office: U.S. DEPARTMENT	OF COMMERCE	
FEE TRANSMITTAL		Application Number			To be assigned		
		Filing Date			Concurrently herewith		
Patent fees are subject to annual revision on October 1. These are the fees effective October 1, 2000.	First Named Inventor			Evgenyi Y. Shalaev, et al			
Small Entity payments <u>must</u> be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.	Examiner Name				To be assigned		
See 37 C.F.R. §§ 1.27 and 1.28.	Group/Art Unit				To be assigned		
Total Amount of Payment (\$)1,102.00	Attorney Docket No.				PC10807ACJG		
METHOD OF PAYMENT (check one)	7			FEE CA	CULATION (continued)		
The commissioner is hereby authorized to charge	3. ADDI	TIONAL F	EES				
indicated fees and credit any over payments to:	Large Entity Small Entity			Entity			
Deposit Account 16-1445 Number	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid	
Deposit Account Name Pfizer Inc.	105	130	205	65	Surcharge – late fee or oath		
Charge Any Additional Charge the Issue Fee Set in	127	50	227	25	Surcharge-late provisional filing fee or cover sheet		
37 Fee Required Under 37 C.F.R. § 1.1.8 at the Mailing	139	130	139	130	Non-English specification		
C.F.R. §§ 1.1.6 and 1.17. of the Notice of Allowance.	147	2,520	147	2,520	For filing a request for reexamination		
2. Payment Enclosed:	112	920*	112	920*	Requesting publication of SIR prior to Examiner action		
Check Money Order Dther	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
FEE CALCULATION	115	110	215	55	Extension for reply within first month		
1. BASIC FILING FEE	116	390	216	195	Extension for reply within second month		
Large Entity Small Entity	117	890	217	445	Extension for reply within third month		
Fee Fee Fee Fee Description Fee Paid Code (\$)	118	1,390	218	695	Extension for reply within fourth month		
101 710 201 355 Utility filing fee 710.00	128	1,890	228	945	Extension for reply within fifth month		
106 320 206 160 Design filing fee	119	310	219	155	Notice of Appeal		
107 490 207 245 Plant filing fee	120	310	220	155	Filing a brief in support of an appeal		
108 710 208 355 Reissue filing fee	121	270	221	135	Request for oral hearing		
114 150 214 75 Provisional filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding		
SUBTOTAL (1) (\$) 710.00	140	110	240	55	Petition to revive - unavoidable		
2. EXTRA CLAIM FEES	141	1,240	241	620	Petition to revive - unintentional		
Extra Fee from Claims below Fee Paid	142	1,240	242	620	Utility issue fee (or reissue)		
Total Claims 24 -20**= 4 X 18 = 72.00	1/13	440	243	220	Design issue fee		

2. 5.	A CLAI	W FEES		1 141	1,240	241	020	retition to revive - utilitieritional	- 1
ĺ			Extra Fee from Claims below Fee Paid	142	1,240	242	620	Utility issue fee (or reissue)	
Total Cla	ims	24 -20**=	4 × 18 = 72.00	143	440	243	220	Design issue fee	
Independ Ciaims	lent	7 - 3**=	4 X 80 = 320.00	144	600	244	300	Plant issue fee	
Multiple (Dependent	t	0 = 0	122	130	122	130	Petitions to the Commissioner	
** or nu. Large	•	viously paid, Small Enti	greater; For Reissues, see below y	123	50	123	50	Petitions related to provisional applications	
Fee Code	Fee (\$)	Fee Fe		126	240	126	240	Submission of Information Disclosure Statement	
103	18	203 9	Claims in excess of 20	581	40	581	40	Recording each patent assignment per property (times number of properties)	
102	. 80	202 40	Independent claims in excess of 3	146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
104	270	204 135	Multiple dependent claim, if not paid	149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
109	80	209 40	**Reissue independent claims over original patent	Other Fe	e (specify)	ŀ			
110	18	210 9	**Reissue claims in excess of 20 and over original patent	Other Fe	e (specify)	1			

SUBMITTED BY		Complete (if Applicable)		
Type or Printed Name	Carl J. Goddard	Reg. Number	39,203	
Signature	Cary, Baceen	Date 3/12/01	Deposit Account User ID	16-1445

*Reduced by Basic Filing Fee Paid

SUBTOTAL (2) (\$)

392.00

SUBTOTAL (3) (\$)